Changes in share wave elastography after Lumacaftor/Ivacaftor treatment in children with cystic fibrosis.

BACKGROUND Lumacaftor/Ivacaftor (LUM/IVA) is an approved combination therapy for cystic fibrosis (CF) patients homozygous for F508del. OBJECTIVE This study aimed to detect changes in liver stiffness measurement (LSM) in patients under this treatment. METHODS The study population consisted of CF patients homozygous for F508del, 6 to 11 years old, that had been treated for six months with LUM/IVA. Shear wave elastography (SWE) was performed in all of them, before and 6 months after the commencement of treatment. RESULTS Thirty-one patients were included in the study. LSM values after treatment were significantly higher than the values before treatment (medians and interquartile ranges of LSM values before and after treatment: 5.6, 5.3-6.3 kPa and, 6.4, 6.0-7.6 kPa, respectively, p<0.001). CONCLUSION SWE can detect early changes in LSM in some CF patients treated with LUM/IVA.